Revenue surged 40% year-over-year in Q4 2024, with improved cash flow and narrowed EBITDA loss as the PPT business model expanded to 50 hospitals. Order collection and R&D pipeline maturity support growth, but outlook remains cautious amid market uncertainties.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.